Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05259696 · OUTCOME

Number of Participants Who Experienced AEs or SAEs

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) · Source last updated 2025-08-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
15 Months

What was measured

Number of participants who experienced an adverse events (AEs) or a serious adverse event (SAE)

Groups in this outcome

E-602 1 mg/kg

Participants received 1 mg/kg E-602 monotherapy administered weekly via IV infusion.

E-602 3 mg/kg

Participants received 3 mg/kg E-602 monotherapy administered weekly via IV infusion.

E-602 10 mg/kg

Participants received 10 mg/kg E-602 monotherapy administered weekly via IV infusion.

E-602 20 mg/kg

Participants received 20 mg/kg E-602 monotherapy administered weekly via IV infusion.

E-602 30 mg/kg

Participants received 30 mg/kg E-602 monotherapy administered weekly via IV infusion.

E-602 20 mg/kg in Combination With Cemiplimab

Participants received 20 mg/kg E-602 monotherapy administered weekly via IV infusion. They also received 350 mg cemiplimab administered every 3 weeks via IV infusion.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
E-602 1 mg/kg5
E-602 3 mg/kg4
E-602 10 mg/kg9
E-602 20 mg/kg15
E-602 30 mg/kg15
E-602 20 mg/kg in Combination With Cemiplimab21

Reported measurements

Participants with any Treatment Emergent AE
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
E-602 1 mg/kg5Not reportedNot reportedNot reportedNot reported
E-602 3 mg/kg4Not reportedNot reportedNot reportedNot reported
E-602 10 mg/kg8Not reportedNot reportedNot reportedNot reported
E-602 20 mg/kg15Not reportedNot reportedNot reportedNot reported
E-602 30 mg/kg15Not reportedNot reportedNot reportedNot reported
E-602 20 mg/kg in Combination With Cemiplimab20Not reportedNot reportedNot reportedNot reported
Participants with any Serious AE
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
E-602 1 mg/kg3Not reportedNot reportedNot reportedNot reported
E-602 3 mg/kg1Not reportedNot reportedNot reportedNot reported
E-602 10 mg/kg1Not reportedNot reportedNot reportedNot reported
E-602 20 mg/kg6Not reportedNot reportedNot reportedNot reported
E-602 30 mg/kg5Not reportedNot reportedNot reportedNot reported
E-602 20 mg/kg in Combination With Cemiplimab5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        5
      2. group Id
        OG001
        value
        4
      3. group Id
        OG002
        value
        8
      4. group Id
        OG003
        value
        15
      5. group Id
        OG004
        value
        15
      6. group Id
        OG005
        value
        20
    title
    Participants with any Treatment Emergent AE
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        6
      5. group Id
        OG004
        value
        5
      6. group Id
        OG005
        value
        5
    title
    Participants with any Serious AE
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    2. group Id
      OG001
      value
      4
    3. group Id
      OG002
      value
      9
    4. group Id
      OG003
      value
      15
    5. group Id
      OG004
      value
      15
    6. group Id
      OG005
      value
      21
    units
    Participants
description
Number of participants who experienced an adverse events (AEs) or a serious adverse event (SAE)
groups
  1. description
    Participants received 1 mg/kg E-602 monotherapy administered weekly via IV infusion.
    id
    OG000
    title
    E-602 1 mg/kg
  2. description
    Participants received 3 mg/kg E-602 monotherapy administered weekly via IV infusion.
    id
    OG001
    title
    E-602 3 mg/kg
  3. description
    Participants received 10 mg/kg E-602 monotherapy administered weekly via IV infusion.
    id
    OG002
    title
    E-602 10 mg/kg
  4. description
    Participants received 20 mg/kg E-602 monotherapy administered weekly via IV infusion.
    id
    OG003
    title
    E-602 20 mg/kg
  5. description
    Participants received 30 mg/kg E-602 monotherapy administered weekly via IV infusion.
    id
    OG004
    title
    E-602 30 mg/kg
  6. description
    Participants received 20 mg/kg E-602 monotherapy administered weekly via IV infusion. They also received 350 mg cemiplimab administered every 3 weeks via IV infusion.
    id
    OG005
    title
    E-602 20 mg/kg in Combination With Cemiplimab
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
15 Months
title
Number of Participants Who Experienced AEs or SAEs
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice